- Report
- October 2024
- 188 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 381 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 250 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2023
- 120 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- September 2024
- 82 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- August 2022
- 118 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2022
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 70 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- March 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- August 2022
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2022
- 113 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- November 2021
- 193 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- October 2021
- 193 Pages
Global
From €3543EUR$3,712USD£2,968GBP

Pegfilgrastim is a type of oncology drug used to treat neutropenia, a condition in which the body does not produce enough white blood cells. It is a long-acting form of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, a type of white blood cell. Pegfilgrastim is used to reduce the duration and severity of neutropenia and the associated risk of infection in patients receiving chemotherapy for certain types of cancer. It is also used to reduce the duration of neutropenia and the associated risk of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.
Pegfilgrastim is available in both brand-name and generic forms. It is marketed by several pharmaceutical companies, including Amgen, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more